Abstract: To investigate whether the width of gastric serosal lesions in advanced gastric cancer patients have a predictive value for peritoneal recurrence and the 5-year survival rate.
INTRODUCTION

G
astric cancer is the third most common cause of cancerrelated death, with the highest mortality rates in East Asia, including China. Approximately 60% of gastric cancers are diagnosed in these regions. 1 The main treatment for gastric cancer is surgery but peritoneal recurrence is the most frequent pattern of metastasis even after curative resection. 2, 3 Since the prognosis of patients with peritoneal recurrence is dismal and the median survival time is only about 6 months, the identification of patients at high-risk of peritoneal recurrence is crucial to allow proper treatment strategies to be developed.
Over the last 20 years, peritoneal lavage cytology (PLC) has been the standard method used to detect peritoneal micrometastasis. However, the sensitivity of PLC for metastasis prognosis has been reported to be only 18%-50% and not all patients with positive peritoneal cytology will eventually develop a peritoneal recurrence. However, even patients with negative peritoneal cytology have developed peritoneal recurrence after curative resection. 4, 5 Other authors have noted that test execution variations might be the reason for the poor diagnostic accuracy of PLC. 6 Therefore, additional approaches to identify definitively peritoneal metastasis are needed.
As up to 50% of patients with serosal invasion are known to develop peritoneal recurrence, even after curative resections, 7 the present retrospective study was carried out to investigate the correlation between the magnitude of serosal changes and the incidence of peritoneal recurrence in order to determine the high-risk factors for peritoneal metastasis.
Patients and Methods
A cohort of 1109 patients with advanced stage, primary noncardia gastric adenocarcinoma 8 were operated on (gastrectomy) between January 1997 and December 2007 in the Department of General Surgery of the Second Affiliated Hospital of Harbin Medical University. Patient pathological and operation reports together with subsequent follow-up clinical evaluation examination data were stored on our outpatient clinical computer database and available to us from remote terminals as required. The majority of the patients underwent total or partial gastrectomy together with a D2 lymphadenectomy performed by experienced surgeons, which closely followed the operation guidelines of the Japanese Research Society for Gastric Cancer. 9 The exclusion criteria for analysis were gastric stump cancer or synchronous malignancy, tumors of the esophagogastric junction, any form of chronic inflammatory disease, the number of lymph nodes retrieved was <15, a definitive M1 classification, and peritoneal recurrence records that were erroneous. It is an indisputable fact that micrometastases are found in the peritoneal cavity of all PT4b stage cancers, and therefore these patients were excluded from the present study. All patients provided written informed consent for the study, which was approved by the Research Ethics Committee of Harbin Medical University.
Extent of Serosal Invasion
The Japanese Classification of Gastric Carcinoma 27 was used as a guide to measure the width of the serosal invasion. Briefly, the entire serous membrane was visualized by opening the resected stomach along the lesser or greater curvature. The largest macroscopical change in the serosal surface was determined as the measurement (serosal invasion width) used in subsequent analysis. The changes were characterized thus: S0, no change (n ¼ 770); Sn, maximum diameter of change 3 cm (n ¼ 113); and Sw, maximum diameter of changes >3 cm (n ¼ 226).
Follow-Up
All patients underwent periodic follow-up examinations and were assessed every 3 months during the first 2 years after surgery, then every 6 months for 3 years and afterwards yearly. During follow-up, patients were evaluated by physical examination, serum tumor markers (carcinoembryonic antigen, CA19-9 and CA125), endoscopy, chest radiography, abdominopelvic ultrasonography, and computed tomography. Survival duration was calculated from the time of surgery to death or the last follow-up date (December 31, 2011). The median follow-up duration was 52.2 months (range 3.8-119.4).
Peritoneal recurrence was determined by positive cytologic findings of ascitic fluid or by reoperative biopsy. Abdominal ultrasonography and computed tomography were performed for suspected clinical recurrence or because of an increase in tumor markers above pathological levels. The proof of peritoneal recurrence usually required sequential imaging that demonstrated progression of metastatic lesions. In rare situations, peritoneal recurrence was detected by the appearance of clinical signs such as intraabdominal mass or intractable intestinal obstruction. Tumors involving the ovaries (Kruchenberg tumors) and Douglas metastases detected clinically or radiologically were counted as peritoneal recurrences. Although some patients had multiple recurrence episodes, only the initial site of peritoneal recurrence was taken into consideration for statistical evaluations.
Statistical Analyses
SPSS (version 19.0; SPSS, Inc., Chicago, IL) was used for all statistical analyses. Data presented as percentages were compared using a Chi-square test; comparisons of 5-year survival rates with different variables among subgroups were analyzed using a log-rank Chi-square test; multivariate analysis was carried out to establish the hazard ratio with different variables. The Cox proportional hazard regression model was used to determine the optimal cutoff threshold for gastric lesion size. P-values <0.05 were considered to be statistically significant.
RESULTS
Threshold Size of Gastric Lesion
To determine the survival rates, changes in the serosal width threshold were calculated at 1 cm interval. The Cox proportional hazard regression model indicates that the optimal cutoff point is given by the largest Chi-square score determined. The most significant difference in survival rates was at the threshold value of 3 cm (Chi-square 136.486, P < 0.0001, HR 3.079, 95% CI 2.550-3.719) ( Table 1) . Correlations Between Clinical Parameters and Peritoneal Recurrence
Peritoneal recurrence occurred in 222 of 1109 patients (20%). As shown in Table 2 , peritoneal recurrence rates were correlated with tumor size, resection type, longitudinal location, serum albumin concentration, lymphatic/venous invasion, and lymph node metastasis status as well as the lesion size, but not with the histologically characterized type of tumor. Positive lymphatic/venous invasion and gastric lesion sizes >3 cm were strong indicators for the risk of recurrence. There was also a correlation between the recurrence rates, with Borrmann cancer types I and II being the most frequently detected cancers (P < 0.001).
When comparing predictive values of serosa changes >3 cm, lymph node metastasis, and serum albumin concentrations 3.5 g/L for peritoneal recurrence, the specificity of serosa changes >3 cm was highest (92.4%), and the sensitivity (71.6%) and accuracy (88.3%) were higher than the sensitivity (68.9%) and accuracy (81.8%) of serum albumin levels, but lower than the sensitivity values (95.5%) and accuracy levels (94%) of lymph node metastasis. Combination of all 3 parameters for peritoneal recurrence prediction led to an accuracy of 93.8%, a sensitivity of 77%, and a specificity of 98% (Table 3) .
Width of Serosal Changes and Clinicopathological Parameters
When the S0 with the Sw patients were compared, all analyzed clinicopathological parameters correlated with the width of the serosal changes, indicating that serosal changes reflect the severity of gastric cancers (Table 4) .
Prognostic Factors for Patients With Advanced Stage gastric Cancers
Single factor analysis for 5-year survival rates revealed that tumor size, the Borrmann cancer type, longitudinal location, serum albumin concentrations, histology type, lymphatic/venous invasion, width of the serosa changes, T staging, and lymph node metastasis staging, but not the resection type, correlated with the 5-year survival rate (Table 5) .
A further multivariate analysis revealed that only the serum albumin concentration, width of serosa changes, depth of tumor invasion, and lymph node metastasis correlated with the 5-year survival rate (Table 6 ). 
Prognostic Factors for Patients With Peritoneal Recurrence
For peritoneal recurrence patients, single factor analyses for the 5-year survival rate revealed that the tumor size, Borrmann cancer type, longitudinal location, serum albumin concentrations, histology type, lymphatic/venous invasion, width of serosa changes, T staging, and lymph node metastasis staging, but not the resection type, correlated with the 5-year survival rate (Table 7) . A multivariate analysis of the factors influencing the 5-year survival rate for patients with peritoneal recurrence showed that only the serum albumin concentration, lymph node metastasis, and width of the serosa changes correlated with 5-year survival (Table 8) .
Taken together, the recurrence rate was higher in patients with serosal changes >3 cm (70.4%) than in patients with serosal changes 3 cm (7.1%) ( Table 2) , and the degree of the serosal changes indicated the severity of the gastric cancer (Table 4 ). In addition, our statistical evaluation of factors influencing the 5-year survival rate of patients with advanced stage gastric cancer showed that the width of the serosa changes correlated with the survival of all patients (Table 6 ), as well as recurrence patients (Table 7) , which was revealed by the Kaplan-Meier curves of all patients (Fig. 1 ) and recurrence patients (Fig. 2) .
DISCUSSION
Although the therapy of patients with locally advanced gastric cancer is continually improving, peritoneal recurrence remains a frequent occurrence in relapsed patients. 10, 11 When patients develop overt peritoneal metastasis after curative resection, the only therapeutic options are palliative surgery or adjuvant chemotherapy, but these treatments are difficult, demanding, and often unrewarding. Several authors have reported that normothermic intraperitoneal chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPC) have some benefit in the prevention of peritoneal recurrence. One randomized trial of postoperative adjuvant intraperitoneal chemotherapy revealed a significant reduction in local and peritoneal recurrences in patients with advanced tumors who underwent normothermic intraperitoneal chemotherapy. 12 Another randomized prospective study demonstrated that HIPC was capable of improving survival times in patients with more advanced stages of the disease. 13 Other authors obtained similar results in favor of HIPC. [14] [15] [16] [17] A proposed strategy to diagnose peritoneal carcinomatosis after gastric cancer surgery is preoperative PLC to identify patients at very high risk before surgery. 18 Fukagawa et al (2010) 19 reported that if intraoperative lavage cytology is positive in type 4 gastric cancer patients the prognosis becomes so poor that multimodality therapy, including perioperative chemotherapy, is essential. Bonenkamp et al (1996) 20 reported that cytological examination of abdominal washings increased the accuracy of staging and improved the selection of patients suitable for curative or palliative resection. In contrast, other studies noted that PLC is insensitive in predicting the development of peritoneal recurrence. 5 In 2010, PLC was incorporated into the 7th edition of the Union for International Cancer Control/American Joint Committee on Cancer staging system as a specific index of peritoneal dissemination. Patients with positive peritoneal cytology without peritoneal metastases are classified as M1, but the sensitivity of positive peritoneal cytology is low, owing to a considerable false negative rate, with the incidence of peritoneal recurrence ranging from 18% to 35%. It is widely accepted that a correlation exists between peritoneal recurrence and serosal invasion in patients with gastric cancer. Malignant cells exfoliated from the serosal lesions are the main reason for the development of peritoneal metastasis. Jeong et al 21 reported that the overall accuracy of macroscopic diagnosis of serosal invasion was 88%, and its sensitivity and specificity was 82% and 89%, respectively, while the extent of macroscopic serosal invasion was proposed to be helpful in planning adjuvant chemotherapy. 22 A few reports have shown that the width of serosal changes is a useful indicator for the prediction of peritoneal recurrence. Several authors have used 2.0, 2.5, or 3.0 cm as the cutoff points and reported that the prognosis of patients with extended serosal changes was significantly poorer than those with narrow serosal changes. [23] [24] [25] Our study revealed that the width of serosal changes in gastric cancer patients is significantly correlated with the recurrence rate (P < 0.001) and the 5-year survival rate (P < 0.001) of surgically treated gastric cancer, as well as the 5-year survival rate of peritoneal recurrence patients (P < 0.001). Other significant correlations between the 5-year survival rate of postoperative gastric cancer patients were the serum albumin concentration 3.5 g/L, depth of invasion, and lymph node metastasis, findings in agreement with previously reported 5-year survival rates correlated with smaller serosal invasion and fewer metastatic nodes in stage IIIA gastric cancer patients. 1 When data predicting peritoneal recurrence were combined (serosa lesion size >3 cm, lymph node metastasis, and serum albumin concentrations 3.5 g/L), the specificity became 98%, the sensitivity 77%, and accuracy 93.8%. Therefore, we suggest, in agreement with a previous study, that serosal changes might serve as a powerful additional indicator for prophylactic adjuvant chemotherapy for gastric cancer patients. 26 In conclusion, based on our findings of correlations between the extent of gastric serosal changes and recurrence, as well as the 5-year survival rates in gastric cancer patients, we propose that the width of gastric serosal changes should be used as an additional indicator for prophylactic postoperative measures to prevent peritoneal recurrence, using adjuvant chemotherapies such as HIPC. 
